EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Disclosure of elevated amyloid status is not associated with long‐term suicidality in a preclinical AD trial

Joshua D Grill, Rema Raman, Charlene Flournoy, Karin Ernstrom, Aimee Pierce, Amanda Smith, Paul Rosenberg, Jeffrey Burns, Jason Karlawish, Paul Aisen, Karen Chilcott Holdridge, Michele Mancini und 3 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.14623 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Joshua D Grill und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Memory Impairments and Neurological Disorder, University of California Irvine, Irvine, Irvine, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Suicidal Ideation, Disclosure, Suicide. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, Eli Lilly, the Alzheimer's Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION The long‐term implications of disclosing Alzheimer's disease (AD) biomarker information to cognitively unimpaired individuals are unknown. METHODS We compared participants who disclosed their elevated amyloid imaging result in a preclinical AD trial to those who disclosed a not elevated result and enrolled in an observational cohort that underwent parallel assessments. Our primary outcome was a score > 0 on the Columbia Suicidality Severity Rating Scale (CSSRS) at any visit; we also considered suicidal behaviors (CSSRS > 5). RESULTS Among 1707 total participants (68% elevated amyloid, mean [standard deviation] age 71.5 [4.7], 60% female, 90% non‐Hispanic White), followed for a mean 218 (74.1) weeks, there were no suicides and few indications of suicidal thoughts ( n = 124 [7%]) or behaviors ( n = 13 [ 0 (odds ratio = 1.6, 95% confidence interval = 0.76, 3.37). DISCUSSION With a structured approach, brain amyloid results can be returned safely. Highlights The Anti‐Amyloid Treatment in Asymptomatic Alzheimer's study was among the first and largest studies to include biomarker disclosure in a population without cognitive impairment. Routine psychological assessment provided a novel assessment of the impact of disclosure in this sample. Learning an elevated brain amyloid result through a protocolized approach was not associated with suicidal thoughts or behaviors compared to a matched cohort who learned they did not have elevated brain amyloid. Future research will be needed to ensure similar safety in more real‐world settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseSuicidal IdeationDisclosureSuicideAmyloidAmyloid beta-PeptidesHumansFemaleAgedMaleBiomarkersPositron-Emission TomographyCohort StudiesAged, 80 and overMiddle AgedBrain

Stichwörter der Autor:innen

biomarkerdisclosurepreclinicalsuicide

Substanzen

BiomarkersAmyloidAmyloid beta-Peptides

Autor:innen und Institutionen

  • Institute for Memory Impairments and Neurological Disorder, University of California Irvine, Irvine, Irvine, California, USA.
  • Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, Irvine, California, USA.
  • Department of Neurobiology and Behavior, University of California Irvine, Irvine, Irvine, California, USA.
  • Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.
  • Department of Neurology, Oregon Health and Science University, Portland, Oregon, USA.
  • Department of Psychiatry and Behavioral Medicine, University of South Florida, Tampa, Florida, USA.

Förderung

  • NIA NIH HHS
  • Eli Lilly
  • the Alzheimer's Association
  • GHR Foundation
  • National Institute on Aging

Zitieren

APA

Grill, J. D., Raman, R., Flournoy, C., Ernstrom, K., Pierce, A., Smith, A., Rosenberg, P., Burns, J., Karlawish, J., Aisen, P., Holdridge, K. C., Mancini, M., Sperling, R., Sultzer, D., & A4 Study Team (2025). Disclosure of elevated amyloid status is not associated with long‐term suicidality in a preclinical AD trial. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14623

Vancouver

Grill JD, Raman R, Flournoy C, Ernstrom K, Pierce A, Smith A, et al. Disclosure of elevated amyloid status is not associated with long‐term suicidality in a preclinical AD trial. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14623

BibTeX
@article{Grill2025,
  author = {Grill, Joshua D and Raman, Rema and Flournoy, Charlene and Ernstrom, Karin and Pierce, Aimee and Smith, Amanda and Rosenberg, Paul and Burns, Jeffrey and Karlawish, Jason and Aisen, Paul and Holdridge, Karen Chilcott and Mancini, Michele and Sperling, Reisa and Sultzer, David and A4 Study Team, A4 Study Team},
  title = {Disclosure of elevated amyloid status is not associated with long‐term suicidality in a preclinical AD trial},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.14623}
}
Kostenlos starten →